Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Next Previous
X
Search
Trial Profile

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary)
  • Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Jan 2024 Results of patients reported outcomes, published in the Cancer
    • 06 Jun 2023 Results of post-hoc analysis assessing racial differences in disease outcomes and BCM between Black and White patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Sep 2022 Planned End Date changed from 31 May 2024 to 29 Mar 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top